IL267086A - Triazine trione derivatives and their use as modulators of neurotrophin receptors and tyrosine kinase receptors - Google Patents

Triazine trione derivatives and their use as modulators of neurotrophin receptors and tyrosine kinase receptors

Info

Publication number
IL267086A
IL267086A IL267086A IL26708619A IL267086A IL 267086 A IL267086 A IL 267086A IL 267086 A IL267086 A IL 267086A IL 26708619 A IL26708619 A IL 26708619A IL 267086 A IL267086 A IL 267086A
Authority
IL
Israel
Prior art keywords
receptor
modulators
tyrosine kinases
neurotrophin
triazinetrione
Prior art date
Application number
IL267086A
Other languages
English (en)
Hebrew (he)
Original Assignee
AlzeCure Pharma AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AlzeCure Pharma AB filed Critical AlzeCure Pharma AB
Publication of IL267086A publication Critical patent/IL267086A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
    • C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
    • C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D251/26—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hetero atoms directly attached to ring carbon atoms
    • C07D251/30—Only oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL267086A 2016-12-21 2019-06-04 Triazine trione derivatives and their use as modulators of neurotrophin receptors and tyrosine kinase receptors IL267086A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE1651706 2016-12-21
PCT/GB2017/053868 WO2018115891A1 (en) 2016-12-21 2017-12-21 Triazinetrione derivatives and their use as modulators of neurotrophin receptor and receptor tyrosine kinases

Publications (1)

Publication Number Publication Date
IL267086A true IL267086A (en) 2019-08-29

Family

ID=60923799

Family Applications (1)

Application Number Title Priority Date Filing Date
IL267086A IL267086A (en) 2016-12-21 2019-06-04 Triazine trione derivatives and their use as modulators of neurotrophin receptors and tyrosine kinase receptors

Country Status (12)

Country Link
US (1) US20200113910A1 (cg-RX-API-DMAC7.html)
EP (1) EP3558320A1 (cg-RX-API-DMAC7.html)
JP (1) JP2020502225A (cg-RX-API-DMAC7.html)
KR (1) KR20190098982A (cg-RX-API-DMAC7.html)
CN (1) CN110167558A (cg-RX-API-DMAC7.html)
AU (1) AU2017380583A1 (cg-RX-API-DMAC7.html)
BR (1) BR112019012709A2 (cg-RX-API-DMAC7.html)
CA (1) CA3046289A1 (cg-RX-API-DMAC7.html)
IL (1) IL267086A (cg-RX-API-DMAC7.html)
MX (1) MX2019007606A (cg-RX-API-DMAC7.html)
RU (1) RU2019120431A (cg-RX-API-DMAC7.html)
WO (1) WO2018115891A1 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11352332B2 (en) 2018-02-26 2022-06-07 AlzeCure Pharma AB Triazine derivatives for treating diseases relating to neurotrophins
GB201810668D0 (en) 2018-06-28 2018-08-15 Stiftelsen Alzecure New compounds
GB201912404D0 (en) * 2019-08-29 2019-10-16 AlzeCure Pharma AB New compounds
CN113057957A (zh) * 2021-03-30 2021-07-02 福建中医药大学 葛杜宁及其衍生物在制备抗氧化药物和/或化妆品及治疗类风湿性关节炎药物中的用途
CN113893334A (zh) * 2021-10-19 2022-01-07 内蒙古医科大学第二附属医院 基于cAMP/PKA-CREB-BDNF信号通路的七氟烷影响抑制剂及其应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2718799A1 (de) * 1977-04-27 1978-11-09 Bayer Ag 1-(4-phenoxy-phenyl)-1,3,5-triazin- derivate, verfahren zu ihrer herstellung sowie ihre verwendung als arzneimittel und wachstumsfoerderer
CA2765030C (en) * 2009-06-09 2015-10-27 California Capital Equity, Llc Triazine derivatives and their therapeutical applications
WO2011070177A2 (en) * 2009-12-11 2011-06-16 Baltic Technology Development, Ltd. Methods of facilitating neural cell survival using gdnf family ligand (gfl) mimetics or ret signaling pathway activators

Also Published As

Publication number Publication date
MX2019007606A (es) 2020-07-29
WO2018115891A1 (en) 2018-06-28
RU2019120431A (ru) 2021-01-22
RU2019120431A3 (cg-RX-API-DMAC7.html) 2021-03-09
AU2017380583A1 (en) 2019-06-27
US20200113910A1 (en) 2020-04-16
CA3046289A1 (en) 2018-06-28
CN110167558A (zh) 2019-08-23
BR112019012709A2 (pt) 2019-11-26
JP2020502225A (ja) 2020-01-23
EP3558320A1 (en) 2019-10-30
KR20190098982A (ko) 2019-08-23

Similar Documents

Publication Publication Date Title
HUS2500016I1 (hu) Diaril-makrociklusok mint proteinkináz-modulátorok
IL274568A (en) COT modulators and methods of using them
ZA201708065B (en) Azabenzimidazoles and their use as ampa receptor modulators
SG11201600055PA (en) Protein tyrosine kinase modulators and methods of use
ZA201800827B (en) Substituted 4-azaindoles and their use as glun2b receptor modulators
SI3436022T1 (sl) Oksisteroli in postopki za uporabo le-teh
IL280213A (en) Altered quinazolinone derivatives and their use as positive allosteric modulators of MGLUR4
HK40015937A (en) Triazinetrione derivatives and their use as modulators of neurotrophin receptor and receptor tyrosine kinases
ZA202000399B (en) Heterocyclylmethylidene derivatives and their use as modulators of mglur5 receptors
HK40014733A (en) Activin receptor type iia variants and methods of use thereof
HK40014732A (en) Activin receptor type iia variants and methods of use thereof
ZA201600856B (en) Protein tyrosine kinase modulators and methods of use
ZA201704416B (en) Heterocyclylalkyne derivatives and their use as modulators of mglur5 receptors
GB201514761D0 (en) Preparation and uses of pyrimidinone derivatives